Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FEMLYV vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of levonorgestrel, a progestin, and ethinyl estradiol, an estrogen; suppresses gonadotropins, inhibits ovulation, alters cervical mucus and endometrium.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy
Prevention of pregnancy (FDA-approved)
FEMLYV (norethindrone acetate/ethinyl estradiol) is administered as one tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo tablets. The dosing regimen is continuous cyclic.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Terminal elimination half-life is approximately 24-30 hours, supporting once-daily dosing in most patients.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Levonorgestrel: CYP3A4; ethinyl estradiol: CYP3A4, CYP2C9, conjugation.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Primarily renal (approximately 60-70% as metabolites, less than 10% as unchanged drug); fecal excretion accounts for about 20-30%.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Approximately 97-99% bound to plasma proteins, mainly albumin and sex hormone-binding globulin (SHBG).
~99% bound to serum albumin and sex hormone-binding globulin.
Apparent volume of distribution is approximately 0.5-1.4 L/kg, suggesting distribution into total body water and some tissue binding.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral bioavailability is approximately 50-70% due to first-pass metabolism.
Oral: ~70% due to first-pass metabolism.
No specific dosing adjustment is recommended based on GFR, as pharmacokinetics are not significantly altered. However, use with caution in patients with renal impairment, especially if fluid retention is a concern.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in patients with hepatic impairment (Child-Pugh class A, B, or C). No dose modification is recommended; alternative contraceptive methods should be considered in patients with hepatic disease.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Safety and efficacy have not been established in pediatric patients below 16 years of age. In postmenarchal adolescents, dosing is the same as adults: one tablet daily for 21 days, then 7 days of placebo.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use in postmenopausal women. No specific dosing recommendations for elderly patients, as FEMLYV is a contraceptive for women of reproductive age.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events from COC use. Women over 35 who smoke should not use COCs.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Cardiovascular disorders,Carcinoma of the breast and reproductive organs,Liver disease,Risk of thromboembolism,Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolic effects,Headache,Bleeding irregularities
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Breast cancer or other estrogen/progestin-sensitive cancer,Liver tumors or active liver disease,Undiagnosed abnormal uterine bleeding,Pregnancy,Current or history of thrombosis,Cerebrovascular or coronary artery disease,Migraine with aura (if over 35),Cigarette smoking (if over 35)
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No significant food interactions. Grapefruit juice may slightly increase estrogen levels but not clinically relevant. Avoid high-fat meals if experiencing nausea.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
FEMLYV (drospirenone and ethinyl estradiol) is contraindicated in pregnancy due to known risks. First trimester exposure is associated with a small increased risk of neural tube defects and cardiovascular anomalies from the estrogen component. Second and third trimester exposure may lead to fetal harm including feminization of male fetuses, urogenital sinus abnormalities, and potential long-term reproductive tract effects. Postnatal effects such as vaginal adenosis and clear cell adenocarcinoma have been reported with in utero diethylstilbestrol exposure, though relevance to FEMLYV is extrapolated.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
FEMLYV components are excreted in human milk. Ethinyl estradiol milk concentration is approximately 1% of maternal serum; drospirenone M/P ratio is not established. Use during lactation may reduce milk production and quality. No data on infant effects; caution advised. Alternative contraception recommended for breastfeeding women.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
No dosing adjustments apply as FEMLYV is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic clearance, volume of distribution) would theoretically reduce efficacy, but use is not recommended.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
FEMLYV is a combined oral contraceptive containing ethinyl estradiol and norgestimate. Monitor for thromboembolic events, especially in smokers over 35. Counsel patients to take at same time daily and to use backup contraception if doses are missed. Efficacy may be reduced with enzyme-inducing drugs.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one tablet daily at the same time each day.,If you miss a dose, follow the package instructions and use backup contraception.,Smoking increases risk of serious cardiovascular side effects, especially if over 35.,Common side effects include nausea, headache, and breast tenderness; these often improve.,Contact your healthcare provider if you experience leg swelling, chest pain, or severe headache.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FEMLYV vs AFIRMELLE, answered by our medical review team.
FEMLYV is a Oral Contraceptive that works by Combination of levonorgestrel, a progestin, and ethinyl estradiol, an estrogen; suppresses gonadotropins, inhibits ovulation, alters cervical mucus and endometrium.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FEMLYV and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FEMLYV is: FEMLYV (norethindrone acetate/ethinyl estradiol) is administered as one tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo tablets. The dosing regimen is continuous cyclic.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FEMLYV and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FEMLYV is classified as Category C. FEMLYV (drospirenone and ethinyl estradiol) is contraindicated in pregnancy due to known risks. First trimester exposure is associated with a small increased risk of neural tube de. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.